سر اور گردن کا کینسر
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
کہاں جانا ہے
اس ٹرائل کے لیے بھارت میں 6 ہسپتال مریض لے رہے ہیں۔
رجسٹری کی سمری (ٹیکنیکل)
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
سپانسر: جانسن ریسرچ اینڈ ڈیولپمنٹ، ایل ایل سی
ClinicalTrials.gov پر NCT07276399
رجسٹری پر آخری اپڈیٹ 25 ستمبر 2026 · ہم نے پڑھا 20 اکتوبر 2026